The pharmaceutical industry is coming out with new product and therapeutic innovations at a rapid pace. For example, cell and gene therapy is one of the many areas exploding with possibilities for novel treatments of formerly life-threatening conditions. The pressure to bring these new treatments to market quickly, efficiently, and with dependable quality has increased accordingly. Alongside this explosion of innovative solutions is an expectation to continuously improve your products and processes.
The Product Development and Product Systems track at the 2018 ISPE Annual Meeting & Expo in Philadelphia, PA, USA will address this paradigm shift with sessions and workshops presented by experienced practitioners who will share their experiences and solutions to today’s challenges.
The Product Development and Product Systems track will explore how new technologies and thinking will change the product development and manufacturing processes, and their impact on the future state of the industry, through the integration of:
The following topics will be covered:
The Product Development and Product Systems track team looks forward to meeting with you in Philadelphia this November to discuss challenges and share knowledge and solutions.
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...